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Abstract
Background: Gonococcal antimicrobial resistance is a global problem. Different resistance plasmids have emerged
and spread among the isolates of Neisseria gonorrhoeae worldwide and in China. We conducted this study to
monitor the plasmid-mediated penicillin and tetracycline resistance among N. gonorrhoeae isolates in Guangzhou
from 2002 to 2012.
Methods: Consecutive isolates of N. gonorrhoeae were collected from outpatients with gonorrhea attending
the STD clinic in Guangdong Provincial Centre for Skin Diseases and STIs Control and Prevention.
Penicillinase-producing N. gonorrhoeae (PPNG) isolates were analyzed by the paper acidometric method.
Plasmid-mediated resistance to tetracycline in N. gonorrhoeae (TRNG) isolates was screened by the agar
plate dilution method. Plasmid types were determined for TRNG and PPNG isolates using polymerase chain
reaction (PCR). Minimum inhibitory concentrations (MICs) to penicillin and tetracycline were detected by the
agar plate dilution.
Results: Of 1378 consecutive N. gonorrhoeae isolates, 429 PPNG and 639 TRNG isolates were identified. The
prevalence of PPNG, TRNG, and PPNG/TRNG increased from 18.3 to 47.1 % (χ2 = 31.57, p < 0.001), from 29.4
to 52.1 % (χ2 = 16.28, p < 0.001) and from 10.0 to 26.2 % (χ2 = 10.46, p < 0.001) between 2002 and 2012,
respectively. Genotyping of plasmids among PPNGs showed that the majority (93.7 %) of the isolates were
the Asian type plasmids, while the African type plasmid emerged in 2008 and rapidly increased to 14.0 %
in 2012 (χ2 = 25.03, p < 0.001). For TRNGs, all 639 isolates carried the Dutch type plasmid. MICs of penicillin
G and tetracycline persisted at high levels and the MIC90s were 32-fold higher than the resistant cutoff
point over 11 years. The prevalence rates of penicillin- and tetracycline-resistant N. gonorrhoeae varied from
90.9 to 91.1 % and from 88.3 to 89.3 % during 2002 to 2012, respectively.
Conclusions: Resistance to penicillin and tetracycline among N. gonorrhoeae isolates remained at high
levels in Guangzhou. The Asian type PPNG continued to spread and Dutch type TRNG was still the
dominant strain. The African type PPNG has emerged and is spreading rapidly.
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Background
Neisseria gonorrhoeae is the causative agent of gonor-
rhea, which is the second most prevalent bacterial sexu-
ally transmitted infection globally. The emergence and
spread of antibiotic resistant N. gonorrhoeae has posed a
challenge for successful control of gonorrhea worldwide.
In recent decades, resistance developed to the antimicro-
bials previously recommended for treatment of gonorrhea,
including penicillin, tetracyclines and fluoroquinolones
[1–3]. Treatment failures regarding extended-spectrum
cephalosporins such as oral cefixime and injectable
ceftriaxone have been documented in Japan and several
European countries, as well as resistance to spectino-
mycin, leading to the concern of no effective antibiotics
for gonorrhea therapy in the near future [4–10].
Two types of N. gonorrhoeae resistance to penicillin
and tetracycline are identified. They are chromosomally
mediated acquisition of mutated genes or loci and plas-
mid-mediated resistance. Plasmid-mediated resistance to
penicillin is due to the production of penicillinase [11].
Three main resistance plasmids (R-plasmids) are associated
with the worldwide emergence of penicillinase-producing
N. gonorrhoeae (PPNG). These main R-plasmids include
an “Asian” R-plasmid of 7.4 kb in length, and its deletion-
derivatives “African” (5.6 kb) and “Toronto” (5.2 kb) [12].
Other types of penicillinase-producing plasmids have also
been described in gonococci, e.g. Nimes, New Zealand,
Australian and Johannesburg [12–15]. High level resistance
to tetracycline (MIC > 16 mg/L) in gonococci are mediated
by a tetM determinant carried on a 25.2 MDa conjugative
plasmid [16]. The restriction endonuclease map of the 25.2
MDa conjugative plasmid from a tetracycline resistant N.
gonorrhoeae (TRNG) strain imported from the United
States has been found to differ from a map derived from a
strain with the 24.5 MDa conjugative plasmid isolated in
the Netherlands [17]. These two types of tetM carrying
conjugative plasmids were designated as “American” and
“Dutch” types, respectively. Subsequent epidemiological
studies have suggested a worldwide distribution for TRNG
isolates [18, 19]. Determination of plasmid-mediated
penicillin and tetracycline resistance among N. gonor-
rhoeae is a useful epidemiologic tool for monitoring
the movement or importation of isolates within a
geographic region. However, the monitoring of these
isolates in Asia is still limited.
Guangdong province in south China has over 100 million
people, and one-quarter of them are migrant population.
As a province that first opened to the world in 1980s,
Guangdong experienced a rapid increase of STIs, including
gonorrhea in the past three decades. In 2012, Guangdong
reported 18,004 gonorrhea cases to the national disease
reporting system accounting for 18.9 % of the total cases
identified in China [20]. Even though we have developed a
gonorrhea reporting system, we still lack a comprehensive
system that systematically monitors the resistance of N.
gonorrhoeae. Our early survey showed that the prevalence
of penicillin resistance had increased from 57.2 to 81.8 %
and PPNG had rapidly increased from 2 to 21 % during
1996–2001 [21]. In order to monitor the change of
penicillin- and tetracycline-resistant N. gonorrhoeae,
and the change of PPNG and TRNG type, we con-
ducted this study in Guangzhou, the capital city of
Guangdong, from 2002 to 2012.
Methods
Ethics statement
The study has been approved by ethics committee of
Guangdong Provincial Centre for Skin Diseases and STIs
Control and Prevention. All patient data were anonym-
ously reported, with no possibility of connecting the iso-
lates to individual patients. In addition, the specimens
used in this study were all clinical residual specimens,
and no personal information was collected, so we did
not need to ask for the participants to sign an informed
consent. We have no longer have any contact with them.
Bacterial isolates
This study was conducted at Guangdong Provincial
Center for Skin Disease and STIs Control and preven-
tion. One thousand three hundred seventy eight con-
secutive isolates of N. gonorrhoeae were collected from
patients diagnosed with gonorrhoea attending our STD
clinic from 2000 to 2012. The isolates were cultured on
Thayer-Martin agar and identified as N. gonorrhoeae
based on colony morphology, Gram staining, oxidase
test and carbohydrate degradation tests (all sugars were
supplied by FLUKA company) as recommended by
WHO [22]. The strains were preserved in freeze-dried
skimmed milk and stored at −70 °C until use. Anti-
microbial susceptibility and plasmid-mediated resistance
were analyzed in December of each year. All the isolates
were revived successfully.
The WHO N. gonorrhoeae reference strains A, E, G and
WHO-97QA3 were kindly provided by Dr Yin Yueping
(National Center for STD control, China). PPNG control
plasmids, pJD4 (Asian type), pJD5 (African type), and
pJD7 (Toronto type) were kindly provided by Dr. J R
Dillon (University of Saskatchewan, Canada). In addition,
we used WHO-G with American type plasmid and
WHO-97QA3 with Dutch type plasmid as the TRNG con-
trol plasmids.
MIC detection and Interpretation of susceptibility
All isolates were examined for susceptibility to penicillin
G (SmithKline Beecham Limited) and tetracycline
(Sigma-Aldrich Co. LLC.) by agar plate dilution method
for MIC and antimicrobial susceptibilities were inter-
preted according to the criteria developed by WHO
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WPR Resistance Surveillance Programme guidelines [22].
For penicillin, isolates with MICs ≥ 1.0 mg/L were classi-
fied as resistant, isolates with MICs of 0.6–0.50 mg/L as
intermediate sensitive, and MICs ≤ 0.6 mg/L as sensitive.
Isolates with MICs ≤ 0.5 mg/L to tetracycline were
classified as sensitive and isolates with MICs > 1 mg/L
as resistant. WHO strains were used as quality con-
trols; the MIC of penicillin to WHO A, E (PPNG)
and G were 0.008 mg/L, MIC > 2 mg/L and 0.5 mg/L,
respectively and the MIC of tetracycline to WHO A,
E and G (TRNG) were 0.25 mg/L,1 mg/L and 32 mg/L,
respectively.
Detection of PPNG and TRNG
PPNG isolates were analyzed by the paper acidometric
method [22]. WHO reference strains A and E were used
as negative and positive controls, respectively. TRNG
isolates were screened by the agar plate dilution method
with the criteria of MIC ≥ 16 mg/L [23].
Genotyping of PPNG and TRNG
DNA extraction [21]: One hundred microliters of the N.
gonorrhoeae isolates suspension (equivalent to McFar-
land No. 1 standard) in distilled water after 18 h’ incuba-
tion were centrifuged at 14,000 g for 30 min. The pellet
was resuspended in 50 μL of lysis buffer (10 mmol/L
Tris HCl pH 7.5, 1 mmol/L EDTA pH 8.0, 0.1 % Triton
and 3000 U/L of proteinase K) and then incubated at
100 °C for 15 min. The supernatant were then used as a
template for PCR amplification.
The Asian (7426 bp), African (5599 bp) and Toronto
(5154 bp) type plasmids of PPNGs were differentiated by
the PCR assays [24]. Four pairs of PCR primers were
used for TEM-1 gene. The tetM gene of TRNG was
amplified to identify American (AR) and Dutch (DR)
variant [25]. A universal forward primer (UF) that
hybridizes with both variants was combined with reverse
primers specific to each variant (AR and DR). The
primer sequences were derived from the sequences of
pOZ100 (UF, AR) and pOZ101 (DR). All primers de-
scribed in Table 1 were synthesized by Invitrogen Bio.
Co. (Shanghai, China).
Four microliters of each extracted DNA from either
reference or clinical isolates were used for amplification
in a 50 μL solution containing: 200 μmol/L (each) dATP,
dCTP, dGTP and dTTP; 50 μmol/L KCl; 10 mM Tris
HCl (pH 8.4); 1.5 μmol/L MgCl2; 0.5 μmol/L of each
oligonucleotide primer and 1.25 U of Taq DNA polymer-
ase (Takara, Japan). Thirty-five cycles of amplification
were performed in a thermocycler (Perkin-Elmer 9600).
Each cycle consisted of 30 s of denaturation at 95 °C, 30 s
of annealing at 55 °C and 1 min of extension at 72 °C.
PCR products were analyzed by electrophoresis in 1 %w/v
agarose and visualized by ultraviolet fluorescence after
ethidium bromide staining.
Statistical analysis
In this study, SPSS 18.0 (IBM) was used for all statistical
analyses. Descriptive analyses were conducted to deter-
mine the distribution of genotype and resistance. In
addition, we also performed trend analysis to test the
trend of resistance during the study period.
Results
PPNG and TRNG prevalence
Of the 1378 consecutive gonococci isolated from 2002
to 2012, 429 PPNG isolates were identified by paper
acidimetric method and 639 TRNG isolates were identi-
fied by agar plate dilution method. The prevalence of
PPNG, TRNG, and PPNG/TRNG increased from 18.3 to
47.1 % (χ2 = 31.570, p < 0.001), from 29.4 to 52.1 % (χ2 =
16.282, p < 0.001) and from 10.0 to 26.2 % (χ2 = 10.462,
p < 0.01) during the study period, respectively (Table 2).
TEM-1 and tetM gene genotyping
The identified PPNGs and TRNGs were further geno-
typed according to the lengths of TEM-1 and tetM PCR
production (Table 2). The results showed that Asian type
plasmids dominated the N. gonorrhoeae isolates during
the study period. However, African type plasmids
emerged in 2008 (1.3 %) and quickly increased to 14.0 %
in 2012 (χ2 = 25.029, p < 0.001). In addition, one Toronto
type was identified in 2012. All of 639 TRNGs carried
the Dutch type plasmids.
Table 1 Primers used for the detection of TEM-1 and tetM in N. gonorrhoeae
Gene Primer Direction Primer sequencea (5′-3′) Reference




tetM UF Forward 825CTCGAACAAGAGGAAAGC842 Turner A et al.25
AR Reverse 1602GCATTCCACTTCCCAAC1586
DR Reverse 1267TGCAGCAGAGGGAGG1253
aPositions are based on the Asian plasmid, Genbank accession number U20374
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MICs of penicillin G and tetracycline
The distribution of MIC50 and MIC90 of penicillin G
and tetracycline from the 1378 consecutive isolates are
summarized in Table 3. MICs of penicillin G and
tetracycline persisted at high level and the MIC90s
were 32-fold higher than the resistant cutoff point
over 11 years. The penicillin-resistant prevalence was
maintained at high levels (90.9 % in 2002 to 91.1 %
in 2012) as were for tetracycline resistance (88.3 % in
2002 to 89.3 % in 2012).
Discussion
Globally, the increasing proportion of PPNG and TRNG
has become a serious concern. PPNG was initially found
in clinical isolates in Thailand and in the United Kingdom
in 1976 [11, 26], and TRNG was firstly found in the
United States in 1985 [27]. Since then, more PPNG
and TRNG were identified and reported worldwide.
Epidemiological studies showed that countries in East
Asia have significantly different distributions of PPNG, for
example, 55 % in India, 33 % in Pakistan, 86 % in Bhutan
in 2007–11 [28], and 79.3 % in Thailand in 2005–7 [29].
In Japan, among the 719 N. gonorrhoeae isolates isolated
from January 2000 to December 2008, only 10 PPNG iso-
lates (1.4 %) were found [30]. In Nanjing, China, PPNG
and TRNG were reported to increase from 8.0 to 44.4 %
and from 1.8 to 32.8 % respectively during 1999–2006
[31]. A high PPNG prevalence of 51.3 and 49.2 % were
maintained while a TRNG increased from 19.6 to 42.1 %
was observed in the neighboring city of Shanghai over
two time periods, 2004–2005 and 2008–2011 [32]. In
Guangzhou, the prevalence of PPNG increased yearly
Table 2 The distribution of types of TEM-1 and tetM among PPNG and TRNG isolates 2002–2012
Year No.of
isolates
PPNG (%) TRNG (%) PPNG/TRNG (%)
No. of
isolates
Type of TEM-1 No. of
isolates
Type of tetM
Asain African Toronto Dutch American
2002 180 33 (18.3) 33 (100) 0 0 53 (29.4) 53 (100) 0 18 (10.0)
2003 115 31 (27.0) 31 (100) 0 0 50 (43.5) 50 (100) 0 20 (17.4)
2004 90 21 (23.3) 21 (100) 0 0 44 (48.9) 44 (100) 0 8 (8.9)
2005 76 18 (23.7) 18 (100) 0 0 35 (46.1) 35 (100) 0 14 (20)
2006 104 27 (26.0) 27 (100) 0 0 40 (38.5) 40 (100) 0 19 (20.2)
2007 95 30 (31.5) 30 (100) 0 0 41 (43.6) 41 (100) 0 29 (23.6)
2008 183 75 (42.0) 74 (99.7) 1 (1.3) 0 108 (59.0) 108 (100) 0 48 (26.2)
2009 151 45 (29.8) 43 (96.6) 2 (4.4) 0 85 (56.3) 85 (100) 0 25 (16.7)
2010 136 51 (37.5) 44 (87.3) 7 (13.7) 0 67 (49.3) 67 (100) 0 33 (24.3)
2011 127 41 (32.3) 33 (81.5) 8 (19.5) 0 53 (41.7) 53 (100) 0 15 (11.8)
2012 121 57 (47.1) 48 (84.2) 8 (14.0) 1 (1.8) 63 (52.1) 63 (100) 0 32 (26.2)
Total 1378 429 (31.1) 402 (93.7) 18 (6.1) 1 (0.2) 639 (46.4) 639 (100) 0 261 (18.9)




MIC50 MIC90 MIC range S (%) I (%) R (%) MIC50 MIC90 MIC range S (%) R (%)
2002 180 4 >32 0.03– >32 1 (0.6) 15 (8.3) 164 (91.1) 2 >16 0.125– >16 21 (11.7) 159 (88.3)
2003 115 16 >32 0.06– >32 0 (0.0) 3 (2.6) 112 (97.4) 2 >16 0.5– >16 23 (20.0) 92 (80.0)
2004 90 4 >32 0.125– >32 0 (0.0) 8 (8.9) 82 (91.1) 4 >16 0.5– >16 12 (13.3) 78 (86.7)
2005 76 16 >32 0.25– >32 0 (0.0) 5 (6.6) 71 (93.4) 4 64 <0.5– >64 15 (19.7) 64 (84.3)
2006 104 8 >32 >32–0.125 0 (0.0) 5 (4.8) 99 (95.2) 8 16 0.5– >64 20 (19.2) 84 (80.8)
2007 95 8 >32 0.06– >32 4 (4.2) 9 (9.5) 82 (86.3) 32 >32 <0.5– >32 17 (17.9) 78 (82.1)
2008 183 8 >32 <0.06– >32 2 (1.1) 16 (8.7) 165 (90.2) 16 >32 <0.25– >32 12 (6.6) 171 (93.4)
2009 151 1 >32 0.125– >32 1 (0.7) 44 (29.1) 106 (70.1) 32 >32 0.25– >32 13 (8.7) 138 (91.4)
2010 136 2 >32 0.125– >32 1 (0.7) 55 (40.4) 80 (58.9) 8 >32 <0.25– >32 17 (12.5) 119 (87.5)
2011 127 2 >32 <0.03– >32 1 (0.8) 22 (17.3) 104 (81.9) 4 >32 <0.125– >32 0 (0.0) 127 (100)
2012 121 4 >32 0.25– >32 0 11 (9.1) 110 (90.9) 4 >32 0.125– >32 13 (10.7) 108 (89.3)
aMIC mg/L, S sensitivity, I intermediate sensitivity, R resistance
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from 2 to 21.8 % and TRNG from 1.5 to 27.2 % dur-
ing 1996–2001 [21]. In the present study, continuing
increases were found from 18.3 to 47.1 % for PPNG
and from 29.4 to 52.1 % for TRNG in 2002–2012.
In this study, we detected the Asian, African, and To-
ronto plasmids among our clinical isolates. The majority
(93.7 %) of the consecutive PPNGs were genotyped as
the Asian plasmid, which was similar to the results in
Nanjing, China, in 1999–2006 [31]. However, the African
type plasmid which was found in 2008 rapidly increased
to 19.5 % in 2011 and 14.0 % in 2012; one Toronto type
was first isolated in 2012. In contrast, different distribu-
tions of R-plasmid types were reported in Bangkok,
Thailand, with 82.3 % African, 8.3 % Asian and 9.3 %
Toronto types in 2005–7 [29], 100 % African type in
Bangladesh in 2012 [33], 50 % African, 40 % Asian and
10 % Toronto types in Japan during 2000–8 [30] and
35.2 % African and 44.4 % Toronto types in South Africa
in 2008 [34]. Our results showed a different trend of
R-plasmid types in Guangzhou from 2002 to 2012. It
is possible that the change over time is the result of
more and more people from Africa and eastern
Asian migrating and doing commercial business in
Guangzhou.
High-level tetracycline resistance in N. gonorrhoeae is
mediated by the tetM determinant. During 1988 to 1995,
518 isolates of TRNG isolated in the United Kingdom
but originating from infections acquired in 39 countries
worldwide were collected and typed by the tetM PCR
assay. The results showed various distribution of tetM
types, 98.3 % (59/60) American and 0.7 % (1/60) Dutch
type in Africa, 40 % (4/10) American and 60 % (6/10)
Dutch type in North, Central and South America, 64.3 %
(36/56) American and 35.7 % (20/56) Dutch type in the
Caribbean, 82 % (248/306) American and 18 % (58/306)
Dutch type in Europe, and 100 % (35/35) Dutch type in
the Far East [25]. In addition, Canada also reported that
Dutch type tetM gene predominated (79.35 %) from
1986 to 1997 [35]. In recent years, 24 % (37/154) Dutch
and 76 % (117/154) American type were found in South
Africa in 2008 [34]. In Bangladesh,98.7 % (377/382)
Dutch and 1.3 % (5/382) American type of TRNG were
reported in 2012 [33]. However, in our study, we only
found the Dutch type TRNG in the past 11 years. Similar
results were reported in Nanjing in 2001–6 [31], Shanghai
in 2004–5 [36] and Chengdu in 1999–2002 [37]. This
finding further confirmed that Dutch type TRNG was
dominant in China.
Penicillin and tetracycline have not been used as the
first- or second-line therapeutic agents to treat gonor-
rhea for many years. During 2002–2012, penicillin and
tetracycline had maintained high MICs in Guangzhou;
this further supports the decision not to use penicillin
and tetracycline to treat gonorrhoea. MIC90s of penicillin
G and tetracycline already reached at least 32-fold of the
resistant cutoff point and were largely in accordance
with previous surveys conducted in Southeast Asia. The
rates of resistance to penicillin and tetracycline were
much higher than the findings of studies conducted in
Pakistan (86.8 % penicillin resistance and 77.6 % tetra-
cycline resistance in 2009) [38], India (68 % penicillin
and 55.4 % tetracycline resistance) and Vietnam (48 %
penicillin and 82 % tetracycline resistance) in 2011 [39].
These rates indicated that South China might have even
bigger challenges regarding resistant N. gonorrhoeae.
In view of increasing resistance to cephalosporins
such a cefixime and ceftriaxone [40], it is recom-
mended that all cases of gonorrhea should also be
covered for concomitant chlamydial infection as dual
antibiotics might delay the onset of cephalosporin re-
sistance [41]. Macrolide resistances N. gonorrhoeae is
relatively low in many countries such as United States
(0.04 %) [42]: and United Kingdom (1.6 % in England
and Wales) [43] although cases have been reported
[42, 44, 45]. In such cases, the choice for covering
chlamydial infection should be a macrolide such as
azithromycin rather than tetracycline such as doxy-
cycline because of high rates of tetracycline resistance
worldwide as well as in China. Furthermore, there is
in vitro evidence of synergy between azithromycin
and cephalosporin as well as more effective eradica-
tion for pharyngeal gonorrhea [46].
Conclusions
In summary, the levels of resistance to penicillin and
tetracycline were consistently high in Guangzhou. PPNG
and TRNG have rapidly increased, in which, the Asian
type PPNG has continued to further spread and the Dutch
type TRNG is still the dominant strain in Guangzhou. In
addition, the African type PPNG has increased in recent
years, while Toronto type had emerged in 2012.
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